KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Net Income: 2009-2025

Historic Net Income for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to -$7.7 million.

  • Arbutus Biopharma's Net Income rose 60.81% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 44.89%. This contributed to the annual value of -$69.9 million for FY2024, which is 4.02% up from last year.
  • Per Arbutus Biopharma's latest filing, its Net Income stood at -$7.7 million for Q3 2025, which was down 408.95% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Net Income peaked at $2.5 million during Q2 2025, and registered a low of -$24.5 million during Q1 2025.
  • Over the past 3 years, Arbutus Biopharma's median Net Income value was -$17.9 million (recorded in 2024), while the average stood at -$15.7 million.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 37.62% in 2021, then skyrocketed by 112.64% in 2025.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Net Income stood at -$21.3 million in 2021, then decreased by 2.87% to -$21.9 million in 2022, then grew by 11.95% to -$19.3 million in 2023, then surged by 35.28% to -$12.5 million in 2024, then skyrocketed by 60.81% to -$7.7 million in 2025.
  • Its Net Income stands at -$7.7 million for Q3 2025, versus $2.5 million for Q2 2025 and -$24.5 million for Q1 2025.